作者
Ameneh Khatami, Matthew D Snape, Elizabeth Davis, Helen Layton, Tessa John, Ly-Mee Yu, Peter M Dull, Christopher J Gill, Tatjana Odrjlin, Simon Dobson, Scott A Halperin, Joanne M Langley, Shelly A McNeil, Andrew J Pollard
发表日期
2012/4/16
期刊
Vaccine
卷号
30
期号
18
页码范围
2831-2838
出版商
Elsevier
简介
BACKGROUND AND AIMS
Serogroup A, C, W-135 and Y meningococcal (MenACWY) conjugate vaccines are recommended for routine adolescent immunisation in the United States and Canada. We evaluated the persistence of bactericidal antibodies through early childhood, following infant immunisation with varying schedules of MenACWY-CRM197 vaccine.
METHODS
UK and Canadian infants were immunised with 2–3 doses of MenACWY-CRM197 or 2 doses of serogroup C meningococcal (MenC) conjugate vaccine, and either MenACWY-CRM197, 1/5 dose of MenACWY polysaccharide vaccine or no booster at 12 months. Control groups recruited at 60 months had received country-specific infant doses of MenC conjugate vaccine. hSBA titres were measured in participants at 40 and 60 months of age.
RESULTS
382 children were enrolled in 12 groups (22–40 per group). By age 60 months, 3–11% of …
学术搜索中的文章
A Khatami, MD Snape, E Davis, H Layton, T John… - Vaccine, 2012